Genmab - ADR

NASDAQ:GMAB   1:00:00 PM EDT
20.30
-0.14 (-0.68%)
4:28:06 PM EDT: $20.50 +0.20 (+0.99%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)12.49B
Current PE11.38
Forward PE 13.44
2yr Forward PE 11.34
See more stats
Estimates Current Quarter
Revenue$911.82 Million
Adjusted EPS$0.40
See more estimates
10-Day MA$20.69
50-Day MA$20.97
200-Day MA$21.42
See more pivots

Genmab - ADR Stock, NASDAQ:GMAB

Carl Jacobsens Vej 30, Valby, Copenhagen, Central Denmark 2500
Denmark
Phone: +45.70.20.27.28
Number of Employees: 2682

Description

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.